Stock Ratings / Health Care / IDYA / options

DYN (40) TLX (54) ELVN (40) BHC (69) ⌘ Pro Terminal →

IDEAYA Biosciences Inc. (IDYA) Options Positioning, Max Pain & Unusual Sweeps

$32.89 -3.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $32.64

IDEAYA Biosciences Inc. (IDYA) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $3.17B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $32.64 (-0.76%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IDYA)Realized 20D OHLCV Swing Band: ±9.1%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY IDYA SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (31% of score)

Altman Z-Score 21.49 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (22% of score)

FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$36.11-9% Next Q

Q2 (-2Q)

Grade C-$32.85+5.7% Next Q

Q3 (-1Q)

Grade D$34.71-5.2% Next Q

Current

Grade D$32.89-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IDYA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IDYA currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($37.24) and Max Pain ($34.53) forces dealer call-delta covering toward $44.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IDYA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IDYA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.1%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (IDYA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for IDYA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IDYA)

✓Walkthrough of IDYA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IDYA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.02%▼ SUPPORT BREAKDOWN

2026-10-30O $32.76H $33.50L $31.70C $32.89VOL 838.0K

RES: $45.50SUP: $36.52SMA50: $37.24SMA200: $34.02

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IDYA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IDYA Butterfly Map → + Track IDYA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IDYA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IDYA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IDYA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IDYA)

Health Care Rank #469 of 1016 ⚔️ DYN vs IDYA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IDYA vs. DYN, TLX, ELVN, BHC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, IDEAYA Biosciences Inc. (IDYA) ranks #469 by composite RQD confidence (45/100, grade D) and #204 by equity capitalization ($3.17B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with IDYA at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IDYA ACTIVE IDEAYA Biosciences Inc.	D	45/100	—	—	-13.8%	-3.15%	$3.17B	Benchmark Subject
DYN Dyne Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.35%	$3.18B	/dyn-vs-idya →
TLX Telix Pharmaceuticals Limited	D+	54/100	—	—	—	+2.70%	$3.22B	/tlx-vs-idya →
ELVN Enliven Therapeutics Inc.	D-	40/100	—	—	-26.2%	+0.67%	$3.30B	/elvn-vs-idya →
BHC Bausch Health Companies Inc.	C+	69/100	21.2x	—	7.6%	+28.76%	$3.33B	/bhc-vs-idya →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001676725

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IDEAYA Biosciences Inc. (IDYA) reported GAAP revenue of $218.7M (+3024.4% vs. FY2024 revenue of $7.0M , and +835.3% cumulative change since FY2023) , GAAP net income of -$113.7M, operating cash flow of -$71.1M, and free cash flow of -$73.5M (+70.8% YoY). On the balance sheet, IDYA closed FY2025 with $1.11B in total assets against $0 in total debt (Altman Z-Score: 21.49, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$218.7M	-$113.7M	-$71.1M	-$73.5M	$1.11B	—
FY2024 (FY)	2024-12-31	$7.0M	-$274.5M	-$247.6M	-$251.4M	$1.12B	—
FY2023 (FY)	2023-12-31	$23.4M	-$113.0M	-$115.2M	-$115.2M	—	—

3. IDYA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IDYA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, IDEAYA Biosciences Inc. (NASDAQ: IDYA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $32.89 (-3.15% 1D, market cap $3.17B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IDYA ranks #469 in composite RQD confidence.

How does IDYA compare to DYN and TLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IDYA carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -13.8%. By comparison, DYN (Dyne Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.18B) and TLX (Telix Pharmaceuticals Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $3.22B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IDYA?

Per IDYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001676725), IDEAYA Biosciences Inc. generated $218.7M in revenue (+3024.4% YoY), -$113.7M in net income, and -$73.5M in free cash flow against $1.11B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IDYA trading relative to its 50-day, 200-day, and 52-week technical levels?

IDYA last traded at $32.89 (-3.15% on volume of 1,623,979 shares), positioning the stock -11.68% below its 50-day simple moving average ($37.24) and -3.32% below its 200-day simple moving average ($34.02). Across its 52-week range of $26.81 to $42.68, IDYA sits at the 38.3% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.1% ($29.90 to $35.88).

IDYA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is IDYA's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for IDYA.

Direct Sub-Reports: IDYA RQD Cockpit IDYA 12M Forecast IDYA Earnings & Move IDYA Dividends & DRIP IDYA Insiders & 13F IDYA Whale Options IDYA Profit Sankey IDYA News & Why